264 related articles for article (PubMed ID: 26566278)
1. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
Madaras L; Balint N; Gyorffy B; Tokes AM; Barshack I; Yosepovich A; Friedman E; Paluch-Shimon S; Zippel D; Baghy K; Timar J; Kovalszky I; Kulka J; Szasz AM
Pathobiology; 2016; 83(1):1-12. PubMed ID: 26566278
[TBL] [Abstract][Full Text] [Related]
2. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
[TBL] [Abstract][Full Text] [Related]
3. Claudin expression in breast cancer: high or low, what to expect?
Ricardo S; Gerhard R; Cameselle-Teijeiro JF; Schmitt F; Paredes J
Histol Histopathol; 2012 Oct; 27(10):1283-95. PubMed ID: 22936447
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
5. [Claudins as prognostic factors of breast cancer].
Szász MA
Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925
[TBL] [Abstract][Full Text] [Related]
6. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype.
Lu S; Singh K; Mangray S; Tavares R; Noble L; Resnick MB; Yakirevich E
Mod Pathol; 2013 Apr; 26(4):485-95. PubMed ID: 23222490
[TBL] [Abstract][Full Text] [Related]
7. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
8. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
Gerhard R; Ricardo S; Albergaria A; Gomes M; Silva AR; Logullo ÂF; Cameselle-Teijeiro JF; Paredes J; Schmitt F
Breast; 2012 Jun; 21(3):354-60. PubMed ID: 22464177
[TBL] [Abstract][Full Text] [Related]
10. Glycoproteins in Claudin-Low Breast Cancer Cell Lines Have a Unique Expression Profile.
Yen TY; Bowen S; Yen R; Piryatinska A; Macher BA; Timpe LC
J Proteome Res; 2017 Apr; 16(4):1391-1400. PubMed ID: 28287265
[TBL] [Abstract][Full Text] [Related]
11. Distinct claudin expression characterizes BRCA1-related breast cancer.
Heerma van Voss MR; van Diest PJ; Smolders YH; Bart J; van der Wall E; van der Groep P
Histopathology; 2014 Dec; 65(6):814-27. PubMed ID: 25041042
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic and prognosis features of Claudin-low breast cancers].
Xu J; Lan KT; Su TH; Li ZF; Wan Y; Gu QQ; Zou PC; Zou X
Zhonghua Bing Li Xue Za Zhi; 2017 Sep; 46(9):634-639. PubMed ID: 28910875
[No Abstract] [Full Text] [Related]
13. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
14. High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
Jääskeläinen A; Soini Y; Jukkola-Vuorinen A; Auvinen P; Haapasaari KM; Karihtala P
BMC Cancer; 2018 Feb; 18(1):223. PubMed ID: 29482498
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
18. Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype.
Rito M; Schmitt F; Pinto AE; André S
Virchows Arch; 2014 Aug; 465(2):185-91. PubMed ID: 24903673
[TBL] [Abstract][Full Text] [Related]
19. Claudin-Low Breast Cancer; Clinical & Pathological Characteristics.
Dias K; Dvorkin-Gheva A; Hallett RM; Wu Y; Hassell J; Pond GR; Levine M; Whelan T; Bane AL
PLoS One; 2017; 12(1):e0168669. PubMed ID: 28045912
[TBL] [Abstract][Full Text] [Related]
20. Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF;
Cancer Invest; 2018; 36(7):378-388. PubMed ID: 30142017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]